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Abstract: Parkinson’s disease is characterized by the progression of the disease from the early 
stages where it still has little functional consequence for afﬂ  icted patients, to an advanced stage 
disease with large consequences in terms of function, quality of life and individual and societal 
costs. Motor ﬂ  uctuations and symptoms of levodopa overdosage may occur in parallel with 
increasing Parkinsonian symptoms. This leads to a narrower therapeutic window which causes 
problems with traditional oral medication. Various ways of optimizing oral treatment should 
be tried but often have limited effects. In addition to the previous alternatives of neurosurgery 
(especially deep brain stimulation of the subthalamic nuclei) and continuous apomorphine 
treatment there is now also the alternative of continuous enteral levodopa adminis  tration via a 
trans-abdominal tube. The effect of the treatment may be tested individually via naso-duodenal 
administration before a decision is made whether to continue with permanent treatment. In the 
present article, the challenges to treatment of Parkinson’s disease in these phases are described 
as well as the various treatment alternatives available. Focus is mainly on the clinical studies 
of continuous levodopa infusion therapies, especially enteral administration of levodopa/car-
bidopa gel. The place of enteral levodopa/carbidopa gel treatment among the other treatment 
methods is also discussed.
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Introduction – Parkinson’s disease 
and its traditional treatment
Parkinson’s disease, as deﬁ  ned by the classical triad of brady-/a-kinesia, rigidity, and 
tremor (Hughes et al 1992), has a prevalence in Europe of approximately 108–257 per 
100,000 according to a recent review (von Campenhausen et al 2005). The majority 
of Parkinson patients have an early phase disease (Hoehn and Yahr stages I-II) with 
symptoms that are, in general, well controlled on standard oral medications. Their 
disease, consequently, causes little handicap and does not affect their quality of life 
to a great extent. The mainstay of treatment during these early phases has, ever since 
its discovery, been oral treatment with levodopa (Olanow et al 2004). Initially, very 
high doses of levodopa were administered with good symptomatic relief but with prob-
lematic side-effects due to the need to administer high doses to overcome peripheral 
degradation. Later on, even more disturbing long-term side-effects developed with 
extreme dyskinesisas being induced in most patients. The situation was improved with 
the discovery and addition of peripheral decarboxylase inhibitors. Since then, a number 
of modiﬁ  cations have been made to increase the pharmacological bioavailability of 
administered levodopa, thus precluding the need to administer the very high doses. 
Even so, involuntary movements develop over time after levodopa treatment has been 
started. A strong trend for developing alternative treatment strategies not associated 
with these problems has been the result, and consequently the dopaminergic agonists 
have recently received much attention as an alternative to levodopa. Agonists are now Neuropsychiatric Disease and Treatment 2007:3(3) 336
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often successfully used in monotherapy or with selegiline 
during the early phases of Parkinson’s disease. However, 
for most Parkinson patients the disease progresses over time 
through these more easily managed phases to a complicated 
disease. This is especially notable for patients in whom 
the disease ﬁ  rst appears early on in life and who, as a result, 
have many years with the disease. These patients have severe 
handicaps, reduced quality of life and the disease severely 
affects their ability to work and function independently in 
society (Dodel et al 2001). In addition to the initial symptoms 
of Parkinsonism, this phase is characterized by severe prob-
lems involving the medication used for symptom relief. Such 
medication-related problems which are largely absent during 
the early phases of illness, strongly affect the ability of the 
treating neurologist to control optimally the symptoms of the 
patient. The problems both affect the motor functioning of 
the patient with a more narrow optimal dosage window 
deﬁ  ned by overdosage and underdosage symptoms, as well 
as cognitive and psychiatric functioning. In addition, other 
non-motor symptoms such as pain and psychiatric problems 
are often accentuated during these later phases.
During these phases the therapeutic alternatives are few 
and a careful evaluation and monitoring of the patients is 
required by neurologists with experience in treating such 
patients. Patients need to be considered individually and treat-
ment regimes need to be individually tailored. Therefore, it is 
important to have a range of different treatment alternatives 
to choose between. The present review focuses on one such 
alternative, that of continuous levodopa administration and 
compares this strategy with other treatments for advanced 
ﬂ  uctuating Parkinson’s disease patients.
Advanced Parkinson’s disease (PD)
The end of the ﬁ  rst, usually reasonably uncomplicated phases 
of PD, is often heralded by a change in the duration of effect 
of each individual levodopa dose. The patient experiences 
reduced functioning before he has taken the next dose of 
medication. This phenomenon is commonly described as 
“end of dose wearing off ”. Initially, wearing off symptoms 
come gradually and in a predictable pattern which can usu-
ally be alleviated by taking the next dose somewhat earlier, 
ie, with higher number of doses per day as a result. Later 
on (though in some patients this might even appear earlier) 
the phases of reduced function may appear more suddenly 
and sometimes in a more unpredictable pattern, not clearly 
related to time of medication. These sudden “off-phases” 
naturally confer upon the patient a feeling of insecurity since 
he or she can never be sure to be able to fulﬁ  l tasks, social 
obligations, and so on, with a good or at least predictable, 
functional level. The patient also feels an increased sensi-
tivity to external factors sometimes beyond the inﬂ  uence of 
the patient, such as stress, the need for unforeseen physical 
exertion, and varying times and compositions of meals. All 
these factors may drastically affect the degree or duration of 
symptomatic relief that the patient experiences from the oral 
medication. A typical example is the patient who goes out 
shopping without any problems initially, only to ﬁ  nd himself 
suddenly frozen in place in the queue of a busy shop, unable 
to pay, move or even to explain his problem to the shop at-
tendants. It can easily be understood that such a situation 
must strongly inﬂ  uence the subjectively experienced quality 
of life (Dodel et al 2001).
Another “new” problem which may appear in patients 
at this stage is the appearance of motor symptoms of over 
dosage. Initially this may be only an internal “restlessness” 
subjectively experienced by the patient. However, for some 
patients this internal restlessness may well be particularly 
noticeable as the more open involuntary dyskinetic move-
ments that may also appear. The dyskinesias most com-
monly appear ﬁ  rst on the expected maximum of the serum 
levodopa curve, so called “peak-dose dyskinesias” but may 
also appear at more or less ﬁ  xed levels of the serum curve as 
it increases or decreases (“bi-phasic dyskinesia”) or even in 
a more random erratic fashion. Dyskinesias also tend to be 
strongly affected by stress and are often worsened in situa-
tions when the patient feels under close observation. Initially 
and with limited amounts of involuntary movements, they do 
not appear to be such an additional burden to the patient as 
one might expect. The patients, in our experience, certainly 
appear keener on avoiding under-functioning than on worry-
ing about involuntary movements.
Too little attention has probably, until very recently, 
been paid to the non-motor symptoms seen in advanced 
Parkinson’s disease, possibly with the exception of hallu-
cinations. Hallucinations have long been recognized as a 
symptom of dopaminergic over activity in advanced patients, 
and often develop in parallel with the above described motor 
symptoms of over dosage. A recent review by Chaudhuri 
and co-authors summarizes the main non-motor symptoms 
(Chaudhuri et al 2006a). These include the following: depres-
sion and anxiety, hallucinations/psychsis, cognitive impair-
ment, constipation, sexual dysfunction, dysautonomic symp-
toms such as orthostatism, pain, and reduced olfaction. Using 
a new 30-item non-motor symptom screening questionnaire 
(the “NMSQuest”), Chaudhuri and co-workers reported 
signiﬁ  cantly higher scores among PD patients for dribbling, Neuropsychiatric Disease and Treatment 2007:3(3) 337
Levodopa for advanced Parkinson’s
impaired taste/smell, impaired swallowing, constipation, 
urinary urgency, weight loss, forgetfulness, sadness, reduced 
concentration, hallucinations, anxiety, sexual dysfunction, 
falling, daytime sleepiness, vivid dreams, and sweating 
(Chaudhuri et al 2006b). There was a signiﬁ  cant association 
with Hoehn and Yahr disease stage and duration showing the 
increased burden of these symptoms in advanced PD. Such 
non-motor symptoms are also important in determining the 
quality of life burden of the disease (Schrag et al 2000; Global 
Parkinson’s disease survey steering committee 2002) and 
nursing home placement (Aarsland et al 2000). There is so 
far insufﬁ  cient evidence regarding the effect of dopaminergic 
treatment both on the development and on the alleviation of 
non-motor symptoms. Certainly any treatment for advanced 
phase Parkinson’s disease should be considered also in this 
light. We ﬁ  nd that especially clear over-dose associated 
symptoms such as hallucinations and orthostatism and off-
related symptoms such as pain and off-period anxiety and 
depression are important factors to consider when treating 
advanced phase patients. In addition, long-term development 
of non-motor symptoms such as cognitive and psychiatric 
functioning must be evaluated for all long-term treatments.
Strategies for the prevention 
of development of motor 
complications
During the last decade, new evidence has been accumulating 
about mechanisms involved especially in the development 
of ﬂ  uctuations. It has been known for a long time that ﬂ  uc-
tuations develop quickly once levodopa treatment has been 
initiated (Olanow et al 2001). This observation has previously 
been taken to suggest that levodopa in itself may be toxic, 
something that has been demonstrated clearly in experimental 
systems in several studies (reviewed by Olanow et al 2004). 
Because of this, many authorities and experts advocate a 
delayed start of levodopa treatment especially for younger 
Parkinson patients, thus hoping to delay the start of the count-
down to ﬂ  uctuations and dyskinesia development (Olanow 
et al 2001). Thus dopaminergic agonists have received 
much attention and are recommended for treatment of early 
Parkinson’s disease (Olanow et al 2001). The agonists are 
not dependent on metabolic change in the remaining dopa-
minergc cells in the brain but are assumed to act directly on 
dopaminergic receptors. Thus, any possible toxicity elicited 
through metabolism of levodopa is avoided. It must be kept in 
mind, however, that once the patient has developed symptoms 
strong enough to cause functional problems, agonists are 
often not enough. There is no other treatment more effective 
than levodopa for controlling these symptoms and treatment 
should then not be withheld due to an exaggerated fear of 
levodopa toxicity (Olanow et al 2004).
There is now considerable evidence that, rather than 
through general substance toxicity, levodopa may cause 
the development of ﬂ  uctuations through the intermittent or 
pulsatile stimulation of dopaminergic systems which is a 
consequence of its short half-life combined with intermittent 
oral dosing schedules (Olanow et al 2004; Stocchi 2005). It 
has been demonstrated that different strategies for smoothing 
out the levodopa stimulation pattern by the early use of 
agonists, as mentioned above as well as with inhibitors of 
levodopa degradation (catechol-O-methyl transferase or 
COMT inhibitors), all delay the development of these com-
plications (Olanow et al 2001; Stocchi and Olanow 2004). 
It thus seems that it is the administration pattern rather than 
the drug itself that is associated with toxicity. There are so 
far no studies of patients treated with continuous levodopa 
already from the early phases of disease.
Alternative treatments 
for advanced disease
Adapted use of oral medication
Oral medication has been, and continues to be, the main 
treatment for the majority of patients also in late phase 
Parkinson’s disease. Standard medication regimes used dur-
ing earlier phases, eg, levodopa three times daily, are only 
rarely sufﬁ  cient. The use of levodopa itself can be modiﬁ  ed 
in various ways to ﬁ  t better the individual patient. Often the 
dosage in terms of milligrams levodopa per day will be a 
compromise between a dose that is sufﬁ  cient to relieve the 
patient from the most disabling symptoms of Parkinsonism, 
and the major overdosage symptoms (especially dyskine-
sias/hyperkinesias and hallucinations). Patients usually tend 
to prefer overdosage to underdosage. The distribution of the 
levodopa intake over the day will often need to be modiﬁ  ed 
with more doses with shorter intervals between doses and 
the patterns of rest/activity and meals over the day may need 
to be coordinated with medication times. Sustained release 
tablets or capsules are often more difﬁ  cult to control and 
evaluate than traditional tablets and are rarely used by most 
neurologists (Widner 2003). However, in some cases, for 
example where compliance for multi-intake dosing is low, 
it may be considered as an attempt to smooth out the serum 
concentration curve somewhat. A perhaps more rational app-
roach is to attempt to reduce the peripheral break-down of Neuropsychiatric Disease and Treatment 2007:3(3) 338
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administered levodopa further by use of COMT inhibitors 
such as tolcapone and entacapone either in addition to the 
previously used levodopa preparations or in combination 
preparations. This strategy has been shown to increase trough 
levodopa levels without increasing peak levels, to prolong 
the effect duration of each levodopa dose, and to improve 
ﬂ  uctuations and reduce dyskinesias (Olanow et al 2001).
A slightly different strategy is the addition of other 
classes of anti-parkinson medications which may even 
out dopaminergic function. In many cases, the addition of 
dopaminergic agonists at this stage of disease may be ben-
eﬁ  cial and serve to reduce ﬂ  uctuations. However, often the 
patient has been on agonists already, since the early use of 
agonists has, in many countries, been recommended as ﬁ  rst 
or second line treatments for early Parkinon’s disease. Thus, 
for many patients the early use of the agonists may lead to no 
further beneﬁ  t when the patient subsequently progresses to 
advanced, ﬂ  uctuating disease. Furthermore, as stated above, 
one of the main non-motor complications of advanced disease 
is hallucinations and this may be aggravated by agonist ad-
dition, precluding their use (Olanow et al 2001). However, 
if the patient tolerates the possible side-effects and does not 
develop hallucinations, improvement of ﬂ  uctuations and 
functions may be observed. Agonists include cabergoline, 
bromocriptine, pramipexole, ropinirole, and pergolide. Of 
these, some are ergotamine derivatives (cabergoline, per-
golide) which have a long half-life enabling attainement of 
a more smooth serum curve. Cabergoline with the longest 
half-life may be dosed once daily. These are theoretically 
attractive characteristics in the context of treating ﬂ  uctua-
tions. However, the ergotamine derivatives have recently 
been suggested to have severe side-effects (pleuropulmonary 
and valvular ﬁ  brosis) which have not been clearly reported 
with non-ergot agonists (Horvath et al 2004; van Camp et al 
2004; Dhawan et al 2005). The discussion is ongoing as to 
whether these side-effects are dose dependent and may be 
prevented by keeping a lower dose, or whether a change to 
non-ergot agonists should be done for these patients.
Continuous agonist treatment
As opposed to levodopa, some agonists have pharmacologi-
cal properties that make them suitable for parenteral admin-
istration subcutaneously or trans dermally. Apomorphine, 
one of the oldest dopamine agonists in clinical use (Schwab 
et al 1951; Frankel et al 1990), has some characteristics 
(rapid uptake, close to 100% bioavailability after subcutane-
ous injection and short time delay to effect) that have led to 
it being utilized as an injectable “rescue drug” for sudden 
severe off states (Steiger et al 1992). A randomized, dou-
ble-blind trial has conﬁ  rmed apomorphine’s effectiveness 
in reducing “off” manifestations (Dewey et al 2001). The 
subcutaneous use of apomorphine is, in an evidence-based 
review by a movement disorder task force, considered to 
be efﬁ  cacious in treating motor complications and reduc-
ing off times (Goetz et al 2006). The use of easily handled 
pen injectors similar to insulin pens may in some cases 
clearly improve the situation for ﬂ  uctuating patients with 
such sudden short offs. For patients in whom the off-state in 
itself is not the problem, but rather the on-off ﬂ  uctuations in 
general and dyskinesias are the central problems, the short 
duration of effect of single injections reduces the utility 
of apomorphine in this form. Some of these patients may, 
however, beneﬁ  t from continuous subcutaneous infusion of 
the drug, a strategy which in spite of the short half-life of the 
drug enables a smooth serum curve to be attained (Nicole 
et al 1993). Modern systems with small pumps similar to 
the insulin pumps used by diabetics are practical and easy to 
carry and maintain. The side-effects include dopaminergic 
and largely dose-dependent ones such as hallucinations and 
nausea especially at start-up. In addition, the medication may 
give local reactions at the injection site such as inﬂ  ammation, 
pigmentation, and ﬁ  brosis which is something that almost all 
patients develop over time (Stocchi et al 2001). Despite these 
side-effects, the treatment has been demonstrated to give a 
lasting improvement of dyskinesias and to reduce off-time 
signiﬁ  cantly (Colzi et al 1998; Stocchi et al 2001; Kanovsky 
et al 2002). In studies evaluating long-term treatment, no 
worsening of neuropsychiatric parameters has been described 
(Di Rosa et al 2003). Dosage of levodopa can be considerably 
reduced without loss of symptom control but some levodopa 
usually must be maintained (Colzi et al 1998; Stocchi et al 
2001). The fact that operative treatment is not required for 
continuous apomorphine treatment is an advantage.
Another substance that has been tested for subcutaneous 
use is the ergot derivative lisuride. This substance also has 
a short half-life and since its solubility is similar to that of 
apomorphine and its oral bioavailability is low, the drug is 
suitable for continuous subcutaneous infusion. Continuous 
subcutaneous infusion of lisuride gave stable serum concen-
trations (Krause et al 1988). Infusion over the long term had 
a good effect on levodopa response with positive effects on 
the size of the therapeutic window between Parkinsonian 
motor underfunction and dyskinesia, but psychiatric side-
effects were common (Vaamonde et al 1991).
Recently, a new attractive strategy for continuous agonist 
treatment has been introduced (Pfeiffer 2005). This involves Neuropsychiatric Disease and Treatment 2007:3(3) 339
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transcutaneous delivery of agonists via a dermal patch or 
through the application on the skin of a microemulsion of the 
agonist (apomorphine in this case) which is then covered by 
an occlusive membrane (Priano et al 2004). Levodopa cannot 
be used in this form due to solubility problems. So far only 
transdermal patch treatment with the new agonist rotigotine 
has reached the stage where it is available for clinical usage. 
It has been tested both for early monotherapy (The Parkinson 
study group, 2003; Poewe and Luessi 2005) as well as for 
late ﬂ  uctuating Parkinson’s disease (Verhagen Metman et al 
2001). Other agonist substances are also under study for 
possible administration via this route, which include lisuride 
mentioned above, as one of the most promising (Pfeiffer 
2005) as well as the rotigotine-like substance 5-OH-DPAT 
(Nugroho et al 2005).
If drugs with sufﬁ  cient symptomatic effect can be easily 
and practically administered transdermally then this may 
represent a new possibility for achieving continuous dopami-
nergic stimulation which may be of beneﬁ  t also to advanced 
Parkinson’s patients. At present it is difﬁ  cult to envisage such 
treatment for this patient category without parallel levodopa 
treatment, and further studies are required to evaluate effects 
on ﬂ  uctuations and dyskinesias as well as other advanced 
stage parkinsonian symptoms.
Neurosurgical therapy
In two large recent reviews, therapeutic alternatives for 
Parkinson’s disease have been considered including therapy 
alternatives for advanced disease with motor complications 
and dyskinesias. In the ﬁ  rst of these reviews, an evidence-
based update on pharmacological and surgical treatments in 
Parkinson’s disease, unilateral pallidotomy was considered 
efﬁ  cacious for treatment of motor complications such as 
dyskinesias and ﬂ  uctuations and for use as a symptomatic 
adjunct to levodopa (Goetz et al 2006). It was regarded as 
“clinically useful” in terms of practiced implications. The 
only other neurosurgical technique for treating Parkinson’s 
disease that was also classiﬁ  ed as efﬁ  cacious and clinically 
useful was deep brain stimulation of the subthalamic nucleus 
(DBS-STN) used as a symptomatic adjunct to levodopa 
(Goetz et al 2006). In an evidence-based review focusing ex-
plicitly on treatment of motor ﬂ  uctuations and dyskinesia, the 
Quality Standards Subcommittee of the American Academy 
of Neurology did not include pallidotomy but only DBS of 
STN, globus pallidus, and thalamus (Pahwa et al 2006). The 
authors concluded that only DBS-STN was possibly effective 
in improving motor function, reducing ﬂ  uctuations, and dys-
kinesias and reducing drug usage, while all other methods of 
DBS had insufﬁ  cient evidence. DBS-STN was recommended 
as a treatment option for these endpoints based on level C evi-
dence (Pahwa et al 2006). In many countries lesional surgery 
has largely been replaced by DBS strategies. DBS has been 
extensively described in a review by Benabid (2003). The 
effect of the treatment is in most patients very good with last-
ing improvement of off-medication motor symptoms (Herzog 
et al 2003; Rodriguez-Oroz et al 2005) and quality of life 
lasting at least 2–5 years (Lagrange et al 2002) (reviewed by 
Diamond and Jankovic 2005). In a recent multicenter study 
reporting results from 69 patients (49 receiving bilateral 
STN and 20 receiving bilateral globus pallidus stimulation) 
lasting dramatic improvement especially of off-state sever-
ity and length per day were seen with both localizations of 
the electrodes (Rodriguez-Oroz et al 2005). In this study, 
levodopa requirement was reduced with STN stimulation but 
not with pallidal stimulation. In another, larger study of 95 
consecutive patients treated with bilateral STN stimulation, 
there was also a clear improvement of off-medication scores 
as well as blinded motor scores and quality of life over 12 
months (Fraix et al 2006). Levodopa dosage was less than 
half of pre-operative values after surgery in this study, other 
studies have reduced levodopa postoperatively slightly less 
(Esselink et al 2004; Rodriguez-Oroz et al 2005).
Side-effects of deep brain stimulation include cerebral 
hemorrhage. This has been reported in 1%–3% of cases 
((Deuschl et al 2003), with some authors reporting higher 
levels (Lagrange et al 2002; Fraix et al 2006) but with only a 
few percent with lasting sequelae. However, some cases have 
resulted in death, and together with other severe complications 
such as fatal postoperative pneumonia, a recent randomized 
trial by Deuschl et al (2006) reported a procedure-related mor-
tality of 2%. Other directly procedure-related adverse effects 
include infections, improper placement of electrodes, transient 
seizures, and confusion. The frequencies of such side-effects 
vary greatly in different reports. Speech problems (mainly 
dysarthria), gait and balance problems, psychiatric problems 
such as depressive symptoms including suicides, as well as 
cognitive decline are other reported side-effects. In long-
term studies such side-effects are frequent (Rodriguez-Oroz 
et al 2005), occurring in the majority of patients. Psychiatric 
side-effects are reported in 8%–20% of patients (Lagrange 
et al 2002; Herzog et al 2003). Most of these are temporary 
but there are also several cases of severe depressions even 
to the extent of including suicide attempts (Lagrange et al 
2002; Burkhard et al 2004). It has been suggested that some 
of these side-effects may be related to the reduced dose of 
levodopa after surgery (Benabid 2003; Deuschl et al 2003). Neuropsychiatric Disease and Treatment 2007:3(3) 340
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In this context it is interesting that pallidal stimulation, which 
does not enable clear reduction of levodopa after surgery, has 
fewer of these side-effects and, indeed, seems to have fewer 
side-effects in general, while possibly being slightly less 
effective in relieving motor symptoms (Esselink et al 2004l; 
Rodriguez-Oroz et al 2005).
Due to perioperative risk and risk of symptomatic intra-
cranial bleeding, a reasonably strict age limit of 70 years has 
usually been practiced in the past. However, this has recently 
been challenged because subgroups of over 70-year-old 
Parkinson patients have been found to have beneﬁ  ted from 
the treatment (Russmann et al 2004; Tagliati et al 2005). 
This issue is also discussed in the AAN review by Pahwa and 
co-workers where older age and longer duration of disease 
are concluded to be predictive of a worse outcome after DBS-
STN (level C evidence) (Pahwa et al 2006). However, the 
main conclusion of this review (level B evidence) was that 
preoperative levodopa response is the best predictive factor 
for outcome of DBS-STN. Fraix and co-workers also found 
on-medication functioning to be the best predicitive factor 
of postoperative motor outcome (Fraix et al 2006)
The total cost of deep brain stimulation has not been ad-
dressed in many studies so far. However, Fraix et al (2006) 
calculated the direct costs before STN operation and up to 
1 year afterwards as well as the costs related to the surgery 
itself (Fraix et al 2006). The 6 month cost decreased from 
€10087 to €1673 after surgery. Surgery-related costs were 
€36904 per patient. However, the follow-up hospitalizations 
and the outpatient controls (total approx €5500 during the 
ﬁ  rst year) were not included in the postoperative costs but 
were regarded as surgery-related costs. In our experience, 
these costs continue since patients need regular polyclinical 
controls often both by a neurosurgical and a neurological 
department for control and adjustment of stimulator function, 
battery level and adjustment of concomitant pharmacologi-
cal therapy. In addition, indirect costs such as employment 
situation and sick leave were not reported and are therefore 
difﬁ  cult to evaluate.
Patients may also have fear of a neurosurgical operation and 
the importance of this should not be underestimated. Patients 
should be approached with an understanding of these fears and 
not with an outright “now or never” ultimatum. This may put 
undue pressure on patients, later on possibly leading to many 
more problems than need be in case they feel pressurized into 
taking an operation and experience side-effects. Proper infor-
mation from a physician with knowledge of the procedure and 
with a good relationship with and knowledge of the patient and 
his or her situation, as well as time, may prevent later problems. 
How many patients offered the treatment decline this offer has 
also not, to our knowledge, been reported so far.
Continuous levodopa treatment
Intravenous
In 1975, Shoulson described 7 Parkinson’s patients 
with severe on/off fluctuations on oral medication who 
were administered intravenous levodopa continuously. 
The administration, encouragingly, led to the virtual disap-
pearance of the ﬂ  uctuations (Shoulson et al 1975). Several 
small additional trials in the UK and the US supported these 
ﬁ  ndings (Nutt et al 1984; Quinn et al 1984). The efﬁ  ciency 
of continuous intravenous treatment in reducing ﬂ  uctuations 
led these researchers to propose the development of strategies 
for continuous treatment with levodopa-analogues for such 
patients (Quinn et al 1984). Hardie and co-workers performed 
a meticulous study focussing mainly on ﬂ  uctuating symptoms 
such as dyskinesias and off-dose dystonias. They used care-
ful monitoring of oral medication with both serum levodopa 
concentration measurements and clinical evaluation of patients 
as well as similar monitoring after i.v. administration and 
response to the dopamine agonists lisuride and apomorphine 
(Hardie et al 1984). Again it was demonstrated that continuous 
intravenous administration gave more stable serum curves and 
that this clearly reduced ﬂ  uctuations. The pharmacochemical 
characteristics of levodopa itself meant that it could only be 
administered intravenously or orally. Especially the low aqeous 
solubility of levodopa made it impossible to consider subcutane-
ous administration since considerable volumes would have been 
required. In the intravenous studies volumes over 2 L of solute 
(saline or dextrose and water) per day with less than 1 mg/mL 
of levodopa were often administered, making this administration 
very cumbersome. The acidity of the infusion substance further 
made thrombophlebitis a distinct possibility, and to reduce this 
risk central venous access was often utilized.
Intra-duodenal
Kurlan and co-workers as well as Sage and co-workers dem-
onstrated that direct intra-duodenal infusion was possible and 
also reduced ﬂ  uctuations to a similar extent to i.v. infusions 
(Kurlan et al 1986, 1988, Sage et al 1988a). An Italian group 
reported a single case with very advanced disease which they 
treated with levodopa methyl ester (250 mg/mL levodopa) 
intra-duodenally, thus considerably reducing volume require-
ments (Ruggieri et al 1989). This group has later continued 
the use of this strategy for enteral levodopa administration 
for more patients with good result (Stocchi et al 1992). Later 
studies have further corroborated this and especially shown Neuropsychiatric Disease and Treatment 2007:3(3) 341
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good improvement of the hyperkinesias and dyskinesias but 
also increased on-times and improved motor scores (Syed 
et al 1998; Stocchi et al 2005).
Pharmacokinetics of levodopa infusion 
therapies
The ﬁ  rst solutions that were used for enteral infusion of le-
vodopa contained 1 g/L levodopa and 250 mg/L carbidopa 
which again meant that large volumes had to be used (Kurlan 
et al 1988). Kurlan et al compared standard oral medication 
of levodopa with levodopa administered either intermittently 
to simulate oral intake patterns but with intragastric or intra-
duodenal administration, or with continuous administration 
to these same sites (Kurlan et al 1988). In 10 patients con-
tinuous intra-duodenal administration gave the best result 
and the lowest coefﬁ  cient of variation of plasma levels of 
levodopa.
In several studies, intra-duodenal levodopa administration 
has been compared to oral medication including sustained 
release tablets. Bredberg found a coefﬁ  cient of variation 
of 45% in 5 patients in a crossover study of 5 patients on 
oral medication which decreased to 12% on intra-duodenal 
medication (Bredberg et al 1993). In a randomized cross-over 
study of the same intra-duodenal levodopa/carbidopa gel 
(Duodopa®) versus levodopa/carbidopa SR tablets a lower 
coefﬁ  cient of variation of the serum concentration was found 
for the intra-duodenal gel administration than for oral tablets 
(14% vs 34%) (Nyholm et al 2003).
Using a different intra-duodenal levodopa solution, Kurth 
et al did a double blind placebo controlled cross over trial in 
10 patients and found a lower plasma levodopa variability 
as compared with oral medication (17% vs 38%) (Kurth 
et al 1993). Only Stocchi et al found plasma variability 
not to be improved by continuous enteral infusion but they 
used the difference between the lowest and highest plasma 
levels and not coefﬁ  cient of variation to address this issue 
in three patients (Stocchi et al 2005). In addition, measure-
ments were collected only hourly suggesting the possibility 
that some of the variability in serum levels may have been 
missed. However, Stocchi et al as well as Sage et al note 
that the troughs in the plasma levodopa curve are avoided 
by continuous infusion ie, that the area under the curve is 
increased and suggest that this mechanism may underlie some 
of the improvement in functional on time per day (Sage et al 
1988a; Stocchi et al 2005).
Using intravenous continuous levodopa administration 
Nutt et al (1984) found that intake of meals high in phenylala-
nine, leucine, and isoleucine reversed the effect of i.v. levodo-
pa despite serum levodopa levels remaining unchanged. This 
suggested that the uptake of levodopa over the blood–brain 
barrier is inhibited by large amounts of these amino acids. In 
a later study, the same authors further demonstrated that part 
of the variability in motor function was explained by plasma 
variations in amino acid levels (Nutt et al 1997). Similar 
results have been found with intra-duodenal administration 
where oral protein intake reduced the effect of administered 
levodopa on motor functioning while serum levodopa levels 
were not affected (Frankel et al 1989).
Intravenous infusion rates required based on several of 
the published iv studies have been approximately 1 mg/kg/
hour of levodopa or about 50–100 mg/hour (Nutt et al 1984, 
1985, 1997; Hardie et al 1984, 1986; Ruggieri et al 1988). In 
intra-duodenal infusions, rates have been very similar with 
about 30–90 mg/hour, although some studies used slightly 
higher levels, above 100 mg/hour.
In studies of infusion administration over a long time, 
plasma levodopa levels were gradually signiﬁ  cantly reduced, 
thus providing evidence against continuous infusion inducing 
tolerance (Nilsson et al 1998). In a study of all 65 patients 
who had been treated with intra-duodenal levodopa/carbidopa 
gel, over 60% of the patients decreased their levodopa dosage 
over the course of the long time treatment, with levodopa 
dosage decreasing by 5% on average between the initial titra-
tion and the last available control visit (Nyholm et al 2006). 
In a study with the aim of observing the effect of continuous 
intravenous levodopa, Schuh and co-workers showed that in 
6 patients with severe dyskinesias, uptitration of levodopa to 
2.4 mg/kg/hour led to a 40% reduction of dyskinesia scores 
with a rightward shift of the dyskinesia dose-response curve. 
The dose-response curve for anti-Parkinsonian effects was 
not shifted, thus leading to a larger therapeutic window and 
suggesting separate mechanisms of the two levodopa effects 
(Schuh and Bennett 1993).
There have been suggestions that administration of 
levodopa over 24 hours without a night time “drug holiday” 
may lead to the development of tolerance (Cedarbaum et al 
1990). However, a recent report of 5 patients on 24-hour 
treatment for 13–37 months showed only a small increase 
in average infusion rates (14%) from start to ﬁ  nal follow up 
with 2 patients reducing their infusion rate slightly (Nyholm 
et al 2005a).
Method of enteral levodopa/carbidopa 
gel (Duodopa) administration
The levodopa/carbidopa gel developed by Neopharma 
AB, Uppsala, Sweden (presently Solvay Pharma GmbH, Neuropsychiatric Disease and Treatment 2007:3(3) 342
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Hannover, Germany) is a carboxymethylcellulose aque-
ous gel containing 20 mg/mL of levodopa and 5 mg/mL of 
carbidopa. It is supplied in cassettes containing 100 mL of 
gel solution (2 g levodopa). The content of the cassettes is 
administered by a portable infusion pump (CADD-Legacy-
Duodopa, Smiths Medical, MN, USA) and via a naso-
duodenal or transabdominal duodenal tube to the duodenum 
proximal jejunum (see Figure 1). For short-term treatment 
and clinical test periods, the naso-duodenal route is used 
to avoid surgery. Fluoroscopy is usually used for correct 
placement of the tube. For longer-term treatment, usually 
after such a test phase, the tube is introduced directly into 
the gastric tract by means of PEG (percutaneous endoscopic 
gastrostomy) surgery and guided to the same position in 
the duodenum/jejunum with the gastroscope. The position 
is later controlled by ﬂ  uorography. All surgical procedures 
are performed using local anesthesia. The pump is carried in 
a special bag or harness with infusion ongoing throughout 
the hours of the day (usually approx. 16 hours). The pump 
is usually stopped at night and a new medication cassette is 
connected every morning.
Clinical studies of levodopa infusion
The promising results of the ﬁ  rst continuous intravenous 
levodopa studies, which showed clear improvement of 
ﬂ  uctuations in patients who had previously been severely 
handicapped (Shoulson et al 1975; Hardie et al 1984; 
Nutt et al 1984; Quinn et al 1984), led to suggestions that 
medication strategies involving continuous dopaminergic 
stimulation should be developed (Quinn et al 1984). Since 
agonists, with the possible exception of apomorphine, are less 
effective than levodopa in controlling Parkinsonian symp-
toms (Olanow et al 2004), not all patients can be controlled 
fully by addition of agonists since dyskinesias often lead to 
a necessity for reducing oral levodopa, with the result that 
the patient becomes under-dosed. In addition, if the patient 
has developed cognitive side-effects and hallucinations, it 
may be necessary also to keep agonist dose at a minimum. 
For these reasons there has continued to be some interest in 
continuous levodopa treatment strategies, with a consequent 
upswing in trials using continuous enteral infusion over the 
long term since the late 1980s (Sage et al 1988a, b, 1989b; 
Nilsson et al 1998; Syed et al 1998; Nilsson et al 2001).
The ﬁ  rst open clinical attempts having produced clear 
improvements of ﬂ  uctuations, Hardie and co-workers did 
one of the few double-blind crossover studies of i.v. infusion 
in 14 patients over 3 days and were able to show signiﬁ  cant 
improvement of motor function (25% median improvement in 
% on-time) and a signiﬁ  cantly reduced number of on-off cycles 
per day (Hardie et al 1984). Similarly other authors demon-
strated almost continuous mobility in a partly blinded study 
over 8 hours with minimal side-effects (Quinn et al 1984).
In studies of intra-duodenal administration, blinded 
placebo-controlled studies have been performed only over short 
periods and using naso-duodenal administration. Signiﬁ  cantly 
increased time in good function was found in parallel with the 
decreased plasma variability described (Kurth et al 1993).
However, as is well known from studies of neurosur-
gical treatment methods such as DBS, clinical studies of 
surgical treatments for Parkinson’s disease pose a number 
of methodological problems. As for neurosurgery, it is 
very difﬁ  cult and ethically almost impossible to envisage 
double-blind, placebo-controlled studies using some type 
of sham operation with placebo administration. In addition, 
due to the strong symptomatic effect and short interval 
between changed administered dose and clinical effect, 
patients notice very quickly whether they have effective 
infusion or not. In addition, the act of simply observing an 
unstable and ﬂ  uctuating Parkinson patient often affects the 
symptoms. Many patients are strongly affected by stress and 
a hospital stay with very different surroundings, food, and 
other circumstances. This presents a very different setting 
compared with the home situation, which is a problem for 
long-term studies. Therefore, combinations of home on-off 
diary self-registration of symptoms and clinical observation 
in the hospital have been used. In order to reduce observer 
bias based on open observational studies, various techniques 
have been used, such as video-based scoring by several in-
dependent investigators as well as less subjective functional 
assessments using electronic movement registration (eg, 
Nyholm et al 2003; Nilsson et al 2001)). Video-scoring may 
also be used in a blinded fashion (see below).
In Uppsala, Sweden, a series of studies using levodopa/
carbidopa gel were done using such strategies to objectify the 
observations regarding motor function (Bredberg et al 1993; 
Nilsson et al 1998; Nilsson et al 2001). In these open studies, 
intra-duodenal adminstration was again compared with stan-
dard oral levodopa and clear improvement in motor function 
was found. Using opto-electronic movement registration and 
video-based on-off scoring in 9 patients, a signiﬁ  cantly im-
proved motor function and reduced ﬂ  uctuations were found. 
The patients were followed openly over long-term treatment 
via a PEG stoma for, on average 4.7 years, with very little 
disease progress seen (Nilsson et al 2001). An increased 
part of the day in functional “near normal” phase was seen 
as compared with the situation at start-up.Neuropsychiatric Disease and Treatment 2007:3(3) 343
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Video-based, blinded, on-off scoring was also used in a 
later cross-over study of 12 patients treated by oral levodopa 
sustained-release tablets or duodenal levodopa/cabidopa 
gel infusion over 3 weeks using naso-duodenal catheters 
(Nyholm et al 2003). These studies veriﬁ  ed the previous 
results of signiﬁ  cantly lower levodopa plasma concentra-
tion coefﬁ  cient of variation with enteral administration and 
a signiﬁ  cantly improved motor function both assessed by 
Uniﬁ  ed Parkinson’s Disease Rating Scale (UPDRS) total 
scores and UPDRS motor subscores. In addition, signiﬁ  cantly 
increased time in functionally good phase (described as “near 
normal” functioning) was seen. In a follow-up study (the 
DIREQT study—Duodopa Infusion: Randomized Efﬁ  cacy 
and Quality of Life Trial), 25 patients participated in a 
3 + 3 week randomized cross-over study using naso-duodenal 
administration of the levodopa/carbidopa gel (Nyholm et al 
2005b). In this study, the treatment alternatives were either 
levodopa/carbidopa infusion via the naso-duodenal route or 
the optimized conventional oral medication that the patients 
were using at baseline. Asssessment was by blinded video-
based on-off recording with conventional therapy patients 
using a dummy tube during videoﬁ  lming. In addition, a home 
diary was used and quality of life parameters were examined 
using PDQ-39 as well as 15D quality of life instruments. 
Analysis was done both based on intention to treat and per 
protocol. Signiﬁ  cantly improved time in good function was 
found as well as signiﬁ  cantly improved quality of life and 
improved total UPDRS as well as subscores of the UPDRS 
I, II, and IV. According to self-assessment diaries there 
were improvements mainly in questions regarding physical 
functioning such as walking, turning in bed, and ability to 
do daily chores, while reports of sleep, feeling depressed and 
dyskinesia did not signiﬁ  cantly differ between the treatments 
(Nyholm et al 2005b). Tolerability was good with only one 
serious adverse effect suspected to be related to infusion 
treatment (confusion and insomnia in a 75-year-old patient. 
The frequency of other side-effects was lower than with the 
conventional treatment.
Information has also been collected on all patients 
treated between 1991 and 2002, for diagnosed Parkinson’s 
disease with ﬂ  uctuations, with levodopa/carbidopa gel (only 
one of all consecutive patients did not agree to participate) 
(Nyholm et al 2007). Adverse effects related to the duodenal 
tube or PEG were the most common and consisted mainly 
of displacement of the duodenal tube. Adverse effects di-
rectly related to the stoma surgery in the gastric wall were 
more rare, as were problems with malfunctioning infusion 
pumps. Altogether, frequency of adverse events was lower 
on the enteral treatment than the frequency of events with 
oral treatment at baseline prior to start of infusion treatment. 
Some patients died while on treatment but the deaths were 
not judged to be procedure or treatment related. Altogether, 
the relative safety of this treatment method seems good also 
in the long run (Nyholm et al 2007). It seems from these 
studies as well as from others that motor effects remain 
stable also over long-term treatment while the natural 
progress of the non-motor Parkinson-related symptoms 
may be less affected.
Figure 1 The administration system used for continuous enteral administration of levodopa/carbidopa gel (Duodopa®).Neuropsychiatric Disease and Treatment 2007:3(3) 344
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A recent statistical analysis of predictive factors for pre-
dicting outcome of levodopa/carbidopa infusion based on two 
studies by Nyholm et al (2003, 2005b) found that the most 
important predictive factors were severity of Parkinsonism 
at baseline (Westin et al 2006). This was assessed as UPDRS 
scores, where motor UPDRS as well as total UPDRS scores 
were signiﬁ  cant outcome predictors. Also, blinded rating 
of on-off percentage at baseline was a signiﬁ  cant predictor. 
As stated by the authors and also from our experience, such 
prediction of outcome based on statistical material is not as 
important as individual test of the treatment based on non-
invasive naso-duodenal administration prior to start-up of 
the more committed invasive treatment. We test each patient 
individually this way and use the individual improvement or 
lack of improvement to predict the ﬁ  nal outcome and decide 
whether the patient should have permanent treatment. We 
have found that results seen on naso-duodenal testing are 
virtually the same as those seen on the ﬁ  nal treatment both 
regarding individual optimized dosage, gain in on-time, and 
UDRS on and off scores (unpublished results).
There have been some other open clinical studies of 
continuous long-term intra-duodenal levodopa using other 
preparations. The group of Syed and Sage and co-workers 
in New Jersey described 22 patients treated (with an aque-
ous solution of 1g levodopa and 250 mg/L of carbidopa) 
on average for 47 months (summarized in Syed et al 1998). 
They compared the group of patients who decided to stop 
infusion therapy with those who continued at the latest 
control or continued until time of death. Both groups had 
signiﬁ  cantly improved % on times compared with tablet 
treatment. In addition, the group who continued treatment 
also had reduced dyskinesia scores and more severe dys-
kinesias at baseline. Levodopa methyl ester has been used 
in studies by Stocchi and co-workers in Italy (Stocchi et al 
2005). In 6 patients treated over 6 months, they found im-
proved UPDRS ADL scores and dyskinesia scores, while 
motor scores in on and off were unchanged. There was also 
a signiﬁ  cant improvement in on time without dyskinesia 
and reduction in off times.
In addition to the use for severely ﬂ  uctuating patients, 
strategies using long-term enteral infusion of levodopa 
have also been used for treating special forms of dyskine-
sias (Sage et al 1989a), and night-time infusion has been 
shown to have good effects on severe sleeping problems 
(Sage and Mark 1991; Nyholm et al 2005a). In our clinical 
experience, one of the major positive effects we have had 
in using this treatment strategy in severe ﬂ  uctuators is that 
the degree of pain that some of our patients have had has 
been clearly reduced (personal observation). These aspects 
of Parkinsonian symptoms deserve to be examined further 
where the possibility to ﬁ  ne titrate the levodopa serum 
concentration can be of considerable advantage. The same 
may also apply to psychiatric symptoms such as depres-
sion and anxiety, which are often very difﬁ  cult to treat in 
patients with Parkinsonism and anti-Parkinsonian medi-
cation. In addition, since psychiatric symptoms are often 
seen as contraindicating neurosurgical treatment, medical 
optimization using continuous treatment strategies may be 
the last resort for these patients.
Lack of comparative studies
As stated above, DBS treatment (especially of the nucleus 
subthalamicus), continuous levodopa, and continuous 
apomorphine treatment seem to focus on the same patient 
categories. So far, in most countries neurosurgical treatment 
has been most commonly used. However, there are as yet no 
comparative studies comparing the three treatments which 
could help to guide our choice in a setting where two or more 
alternative treatments may be available.
A few studies compare the hitherto most common treat-
ments, apomorphine versus DBS. Similar efficiency in 
reducing off time was found in an open non-randomized 
study (12 + 13 patients), with both treatment types (51% 
for apomorphine and 76% for DBS) (de Gaspari et al 2006). 
Abnormal movements were reduced only by DBS. Only 
DBS-treated patients, however, had worsening of neuro-
psychatric index scores after 12 months.
Few treatment centers have more than one of these alter-
native treatment methods in their arsenal. In most Western 
countries there is a possibility of referring at least younger 
patients and patients without cognitive or psychiatric prob-
lems to evaluation of neurosurgical treatment. If available, the 
other methods have so far mainly been reserved for patients 
where neurosurgery is felt to be contraindicated. In the past, 
continuous apomorphine has been more readily available in 
most countries but there has, during the past decade, been an 
upswing in availability of enteral levodopa. This has been 
especially in the Scandinavian countries, the UK, and USA, 
and recently the levodopa/carbidopa gel has been registered on 
the European and Scandinavian markets (Duodopa). Different 
treatment centers prefer different methods for their patients, 
usually based on the treatments that they are most familiar with 
and which are most readily available to them. Table 1 illus-
trates pros and cons to consider in the comparison between the 
three treatment methods. Comparative studies where patients 
are randomized to one treatment or the other to enable direct Neuropsychiatric Disease and Treatment 2007:3(3) 345
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head-to-head comparison of indications, effect, side-effects, 
and costs are urgently needed.
Costs of Parkinson’s disease 
and its treatment
The total costs of Parkinson’s disease have recently 
been addressed based on studies in 5 European countries 
(Lindgren et al 2005). There are only a few studies and many 
uncertainties but some approximations may be made. Thus 
the mean total cost per year is €10,000–20,000 with slightly 
more than half of this as direct costs (including drug costs) 
and the rest as indirect costs. However, it was clear that costs 
increased dramatically as Parkinson’s disease progressed, 
with Hoehn and Yahr stage 5 patients totaling €20,000 to 
€30,000 while the cost associated with stage 1 patients was 
about 20%–25% of this.
Neurosurgery is associated with high surgery-associated 
costs but lower yearly costs after successful surgery (surgery-
related €36900, yearly costs after surgery €1673) (Fraix 
et al 2006). However, control costs after surgery (€5500) 
were not included in the yearly costs, and it is our experi-
ence that these costs continue since further anti-Parkinson 
medication is also almost always required after surgery. In 
addition some controls are required for the stimulator system 
including battery change and further adjustment. It would 
seem reasonable to expect yearly costs at the level of an 
average Parkinson patient also after surgery, ie, in the range 
of €10,000–20,000. One decisive factor when calculating 
yearly costs of neurosurgical DBS therapy is the number of 
years over which the surgery-related and device-related costs 
should be discounted.
Apomorphine costs vary greatly in the published literature 
depending on whether total cost for subcutaneously admin-
istered apomorphine (including subcutaneous injections) or 
just continuous subcutaneous infusion treatment is included. 
A German study by Dodel et al (1998) based on retrospective 
analysis of 409 patients found that the apomorphine patients 
(with continuous subcutaneous infusion) among these had 
medication costs of approximately €13,500 per year. This 
was just over 3 times as much as conventionally treated 
advanced Parkinson patients (Hoehn and Yahr stages IV-V). 
In a small analysis based on pure medication costs of a few 
patients in Germany using apomorphine pump treatment, 
the yearly medication cost was estimated at €73,000–91,000 
(Meissner et al 2001).
Duodopa, in comparison, is also an expensive treatment 
with simple medication costs of almost €50,000 per year in 
Europe. One study has been peformed of Duodopa treatment 
costs but results have so far only been presented in oral and 
abstract form (Kristiansen et al 2005). According to this, 
two years of Duodopa treatment costs US$93,600 which 
should be compared with US$28,700 for the previous con-
ventional treatment. The cost per additional quality adjusted 
life year based on these calculations was US$1.02 million 
Table 1 Factors to be considered in choice between various treatments for advanced ﬂ  uctuating Parkinson’s disease
Neurosurgery (DBS of the STN, pallidotomy)    Pros: Well established, good effect on motor complications when used as an adjunct to levodopa 
(reduces ﬂ  uctuations and dyskinesia), lasting effect, may be cheaper (though total cost uncertain)
   Cons: Major surgery with larger peroperative risk, small risk of IC bleeding, risk of worsening 
of depression and cognitive function, risk of speech problems/dysarthria and gait problems, not 
individually testable, irreversible, (pallidotomy (unilateral) possibly associated with less risk), 
also requires levodopa, continuous technical support required at high level
Continuous subcutaneous apomorphine    Pros: Reasonably well established, good effect especially in treating motor complications and 
reducing off-time, non-invasive method, individually testable without committed surgical step, does 
not require surgery, easily reversible, no worsening of depression or cognition, small pump and 
subcutaneous administration, technical support may be easier due to subcutaneous technique
   Cons: Local side-effects in most patients (ﬁ  brosis and local inﬂ  ammation), tolerance? 
Problematic side effects for some especially at start up (nausea), cumbersome individual 
titration, many patients require levodopa as well, cost? 
Intra-duodenal levodopa gel    Pros: Good effect in treating ﬂ  uctuations, improving on time and reducing off, most effective 
for worst patients, approved treatment, uses most symptomatically effective drug, monother-
apy without need for additional oral medication possible in most, individually testable without 
operation, reversible, minor surgical procedure/risk, rare and predictable adverse effects (based 
on oral treatment), adverse reactions
   Cons: Cumbersome individual titration, need to carry large pump, continuous technical 
support required esp. regarding pump and tubing problems during ﬁ  rst year, cost, requires 
minor surgery for long-term treatmentNeuropsychiatric Disease and Treatment 2007:3(3) 346
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which, according to these authors, is above conventional 
cost-effectiveness thresholds. However, there are several 
uncertainties associated with these calculations warranting 
careful interpretation of the results. The present day status of 
Duodopa as an orphan drug also naturally affects treatment 
costs and the price may thus also change in the future.
What is clear, however, is that the cost of administration 
of duodenal levodopa must be weighed against improvement 
in quality of life for treated patients. Further studies regarding 
this are necessary. At present, cost may be the greatest single 
factor preventing the more widespread use of this treatment.
Conclusion – place of intra-duodenal 
levodopa in treatment of ﬂ  uctuating, 
advanced phase Parkinson’s disease
Continuous administration of levodopa given intra-
duodenally via an intestinal tube with the tip in the duode-
num/proximal jejunum is a safe treatment method with a 
clear clinical gain for advanced Parkinson patients ﬂ  uctuat-
ing between hyper-/dys-kinesias and off-phases. The only 
commercially available such treatment involves the use of 
levodopa/carbidopa caboxymethylcellulose gel, which is 
also the most well-documented method. It is an invasive 
method but involves only minor surgery performed under 
local anesthesia. However, the surgical risk, although small 
and in our view acceptable for most advanced Parkinson 
patients without serious comorbidity, must not be ignored. 
The treatment, therefore, has its place only after oral non-
invasive treatment possibilities have been optimally tried and 
when these no longer are deemed sufﬁ  cient.
Indications for the treatment are similar to indica-
tions for the alternative treatments using stereotactic 
brain surgery (especially DBS of the subthalamic nuclei, 
possibly pallidotomy) and continuous subcutaneous apo-
morphine infusion. Patients must have levodopa-respon-
sive Parkinson’s disease fluctuating between off-phases 
and dyskinetic/hyperkinetic phases in such a way that 
the patients’ function and quality of life are reduced. 
Patients should be cognitively intact enough to manage 
the administration system (possibly with help from home 
nurse or relatives) and not severely affected by psychiatric 
symptoms such as uncontrolled depression or psychosis. 
Psychiatric complications, especially depression, may be 
less of a counter-indication against enteral levodopa and 
apomorphine than for deep brain stimulation though more 
data are required regarding this. Age alone need not be a 
counter-indication for continuous medical treatment.
The lack of direct comparator studies makes evaluation 
of comparative treatment effects difﬁ  cult to evaluate. Due 
to a combination of the neurosurgical treatments being more 
readily available and there being more documentation on their 
effects, a major group of patients for enteral levodopa and 
apomorphine, so far, have been patients considered for, but 
not offered, neurosurgical treatment. This may be because of 
age, comorbidity with increased surgical risk, or psychiatric 
problems. In addition, some patients who have previously 
been unsuccessfully or insufﬁ  ciently treated by neurosurgery 
may also be candidates, as well as patients admitted for 
neurosurgery but who have long time delays before surgery 
can take place. Also patients not wishing surgery of the brain 
are possible candidates for the less invasive techniques. 
Whether or not continuous infusion of levodopa should also 
be considered in younger patients, and its placement on the 
treatment ladder relative to neurosurgery, are questions that 
are yet to be answered. Effect, especially long-term effect, 
and side-effects, as well as risk, costs, and quality of life are 
all factors that must be considered.
Regarding treatment costs, not enough data have been 
published so far to enable choice between the three treat-
ment methods based on cost, though it is clear that all three 
treatments are expensive. It may be that neurosurgery is 
slightly less costly but costs for ineffective neurosurgery and 
follow-up treatment as well as for potentially more serious 
complications should also be considered.
It is possible to test the method for enteral levodopa treat-
ment individually via naso-duodenal administration, prior to 
any invasive surgical steps. This enables a better basis for 
a decision about treatment both on the part of the physician 
and the involved patient. We would suggest that such a test 
should always be made before surgery. Such a test enables 
the patient and the physician to make better informed and 
individually based decisions about treatment. Similarly, 
apomorphine treatment does not require a committed step 
involving surgery before treatment can be tested.
The inclusion of enteral levodopa in the treatment arsenal 
thus enables more individually tailored treatment of a small 
but complicated group of patients. Further results from ongo-
ing studies and clinical series will further clarify criteria for 
optimal selection of the target population.
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